Navigation Links
FDA Looks to Improve Design and Cleaning Instructions for Reusable Medical Devices
Date:4/29/2011

SILVER SPRING, Md., April 29, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced steps to help reduce the risk of exposure to improperly reprocessed devices that can lead to the transmission of disease.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Medical devices intended for repeated use are commonplace in health care settings. They are typically made of durable substances that can withstand reprocessing, a multistep process which includes cleaning, disinfecting, or sterilization to remove debris and biologic materials that may transmit infection between patients. While successful reprocessing of reusable devices occurs routinely in health care settings, there are some devices which present particular challenges to reprocessing.

Based on its access to premarket and postmarket data on reprocessed devices, the FDA identified device design features that reduce the likelihood of retaining debris and that facilitate proper reprocessing. These features include smooth inner surfaces of devices with long, narrow interior channels, clear identification of components that must be discarded after patient use, and designs that take into account how fluid moves through reusable medical devices.

On June 8-9, 2011, the FDA will sponsor a public workshop to discuss these findings and collaborate with representatives from other government agencies, manufacturers, health care providers, and other stakeholders on future device design and scientific advances in reprocessing.

"Reprocessed devices play an integral role in health care. The FDA, industry, and health care facilities share the responsibility of making sure that reprocessing procedures work and are properly implemented," said William Maisel, M.D., M.P.H., deputy director for science at the FDA's Center for Devices and Radiological Health.  

One example of a reu
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Forecast Looks Good for India Pharma Shows
2. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
3. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
4. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
5. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
6. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
7. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
8. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
9. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
10. Surgeons Find That Laparoscopic Banding Procedure Helps Overweight Adolescents Lose Weight and Improve Health
11. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 17 Innocoll, Inc., a privately-held,biopharmaceutical company, ... phase,2 clinical trials sponsored by its wholly ... GENTAMICIN TOPICAL for the,treatment and prevention of ... GENTAMICIN TOPICAL is a biodegradable and fully ...
... Biosciences,Incorporated (Nasdaq: KOSN ) presented preclinical data ... in vitro and in vivo,activity as well as ... NEI anticancer mechanism of action correlating inhibition,of the ... cancer cells,compared to normal cells. Data on Kosan,s ...
Cached Medicine Technology:Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 4Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 4
(Date:4/23/2014)... research, published in the journal Oncotarget , ... different appearances or their own DNA signatures within ... difficult to design effective, targeted treatment strategies. , ... EGFR mutation and either the KRAS or BRAF ... by the EGFR gene mutation have that specific ...
(Date:4/22/2014)... is a popular high school sport in the United ... study by researchers in the Center for Injury Research ... to compare and describe the occurrence and distribution patterns ... high school athletic training setting among adolescents and teens. ... of Athletic Training , examined data relating to adolescents ...
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... 2014: The Association for Molecular Pathology (AMP) released ... Molecular Diagnostics on recommendations for a molecular ... levels of education. The report was prepared by ... of the AMP Training and Education Committee. "Our ... educating future medical laboratory scientists appropriately in order ...
(Date:4/22/2014)... is available in German . ... intracellular signaling molecules, but their mode of action is ... cellular function and behavior, while at high concentrations they ... DNA. To analyze how redox signaling unfolds in single ... technique has been developed jointly by the teams of ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Neuroimaging: Live from inside the cell 2
... FairWarning, Inc. a provider of healthcare privacy auditing ... titled Addressing Electronic Health Record Privacy ... The Webinar will feature John Wade, ... Robert Sullivan of PricewaterhouseCoopers, Healthcare Advisory ...
... Tour Shows Dramatic Impact of AIDS on Children, ... Funds for Social Causes, CINCINNATI, Feb. 13 ... Network (TPN), has partnered with World,Vision to produce ... a national tour designed to raise awareness about ...
... Monitoring Committee holds third meeting -, ... Life Sciences,Inc. (TSX: BNC), a research-based, technology-driven ... update on the progress,of its North American ... - trademarked Urocidin - in patients with ...
... Most Fertile ... Throughout Entire Month, PRINCETON, N.J., Feb. 13 Trying to predict ... provide,only a handful of chances to identify the two most fertile days ... most fertile,days: The new FIRST RESPONSE Daily Ovulation Test includes 20 testing,sticks ...
... for heart, pneumonia care, ST. PAUL, Minn., Feb. ... metro area in three key areas of a,national quality ... heart attack, heart failure and pneumonia care, according to,The ... "We,re very proud of the ongoing quality improvement work ...
... GARDENA, Calif., Feb. 13 Consumers today are ... away from,carbs, while other experts say that the ... we take in each day. The answers may ... oldest populations on earth, namely,Japan., Zojirushi ( ...
Cached Medicine News:Health News:FairWarning to Host Webinar Featuring HIMSS Chairman and Healthcare Executive from PricewaterhouseCoopers on Electronic Health Record Privacy and Compliance Challenges 2Health News:The Brand Experience Teams With World Vision to Launch 'Experience: AIDS' Multi-Media Exhibit 2Health News:The Brand Experience Teams With World Vision to Launch 'Experience: AIDS' Multi-Media Exhibit 3Health News:Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM) 2Health News:Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM) 3Health News:New FIRST RESPONSE(R) Home Ovulation Test Takes the Guesswork Out of Conception 2Health News:Busting the Myth, One Bowl at a Time 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
For use with catalog #0540....
Determination of FDP in Plasma by Latex Agglutination, 60 tests.Microlatex particles coated with mouse monoclonal anti-human FDP antibodies....
Medicine Products: